Showing 5501-5510 of 8888 results for "".
- Coming Soon to a City Near You: Sciton Inc.'s Bright Lights Big City BBL 2018 Tourhttps://practicaldermatology.com/news/coming-soon-to-a-city-near-you-sciton-incs-bright-lights-big-city-bbl-2018-tour/2457815/Sciton. Inc.’s Bright Lights Big City BroadBand Light (BBL) 2018 Tour is now in its third year. The 2018 Tour, featuring San Francisco dermatologist Patrick Bitter Jr., MD, kicks off in early June in For
- With New Team, Revance Readies for Launch of their Botox Competitorhttps://practicaldermatology.com/news/with-new-team-revance-readies-for-launch-of-their-botox-competitor/2457819/With the advent of four new positions, Revance Therapeutics is expanding their commercialization team in anticipation of the product launch of for DaxibotulinumtoxinA for Injection (RT002) in the treatment of glabellar lines.
- BTL to Showcase Groundbreaking Research, Latest Innovation at American Society for Laser Medicine & Surgery Annual Conferencehttps://practicaldermatology.com/news/btl-to-showcase-groundbreaking-research-latest-innovation-at-american-society-for-laser-medicine-surgery-annual-conference/2457817/BTL has had nine scientific abstracts and four ePosters accepted for presentation at the 38th Annual Conference of the American Society for Laser Medicine & Surgery (ASLMS) tak
- ASDSA Applauds USPSTF Endorsement of Behavioral Counseling to Prevent Skin Cancerhttps://practicaldermatology.com/news/asdsa-applauds-uspstf-endorsement-of-behavioral-counseling-to-prevent-skin-cancer/2457820/The American Society for Dermatologic Surgery Association (ASDSA) applauds the recent US Preventive Service Task Force (USPSTF) endorsement of behavioral counseling to prevent skin cancer for individuals aged six months to 24 years
- Escalier Biosciences Closes Financing, Focuses on Psoriasishttps://practicaldermatology.com/news/escalier/2457821/Escalier Biosciences BV, a privately held biopharmaceutical company, this month closed $19 million Series B financing. The round was led by Forbion with existing investors New Science Ventures and BioGeneration Ventures (BGV) completing the round. Escalier is developing both topic
- Hydrogen Peroxide 40% Less Cytotoxic Than Cryotherapy: Studyhttps://practicaldermatology.com/news/hydrogen-peroxide-40-less-cytotoxic-than-cryotherapy-study/2457822/Hydrogen peroxide topical solution 40% (Eskata, Aclaris) is less cytotoxic to living cells and less damaging to melanocytes than cryosurgery, according to a new study led by Adam Friedman, MD, associate professor of dermatology at the GW School of Medicine and Health Sciences. <
- Skin of Color Society Reports Banner Yearhttps://practicaldermatology.com/news/skin-of-color-society-reports-banner-year/2457824/Kudos to the Skin of Color Society (SOCS) for a banner year. At its recent annual business meeting held in conjunction with the 2018 Annual Meeting of the American Academy of Dermatology, SOCS President Seemal R. Desai, MD, President &
- Researchers Assess Tools to Measure QoL Impact of Skin Conditionshttps://practicaldermatology.com/news/researchers-assess-tools-to-measure-qol-impact-of-skin-conditions/2457827/Boston University School of Medicine researchers have set out to find the best tool to measure the impact of skin coniditons on patients' quality of life. Several dermatology and disease-specific tools have been developed to measure the impact of skin disease including the widel
- EpigenCare Named as Johnson & Johnson Innovation Finalist in Skincare Challengehttps://practicaldermatology.com/news/epigencare-named-as-johnson-johnson-innovation-finalist-in-skincare-challenge/2457829/EpigenCare Inc., a personalized skincare startup company, is a finalist in Johnson & Johnson Innovation’s Digital Beauty Quickfire Challenge. The Challenge
- FDA Approves Label Update for Cimzia Addressing Low Risk of Fetal Exposurehttps://practicaldermatology.com/news/fda-approves-label-update-for-cimzia-addressing-low-risk-of-fetal-exposure/2457828/The FDA has approved a label update that includes pharmacokinetic data showing negligible to low transfer of Cimzia® (certolizumab pegol) through placenta and minimal transfer to breast milk fr